Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Octreotide LAR Depot

Peptide · Agonist of somatostatin receptor 2 (SSTR2) · developed by Lexicon Pharmaceuticals

Phase 2 Most advanced trial (none active)

LXRX Developer

1 Registered trials

What is Octreotide LAR Depot?

Octreotide LAR Depot is a long-acting somatostatin analog administered subcutaneously once monthly. It acts as an agonist at somatostatin receptors to suppress hormone secretion. It is studied in carcinoid syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: somatostatin receptor 2 (SSTR2)
Mechanism: Agonist of somatostatin receptor 2 (SSTR2)
Therapy area: Oncology
Developer: Lexicon Pharmaceuticals (LXRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00853047	Phase 2	Carcinoid Syndrome	Completed	LXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoid Syndrome

Other drugs acting on SSTR2

VMT-α-NET Phase 1/2

More from Lexicon Pharmaceuticals

Sotagliflozin FDA approved LX7101 Phase 1/2 LX9211 Phase 2

Sources

ClinicalTrials.gov NCT00853047

Updated Oct 3, 2026. Something wrong or missing? Report it on the LXRX page.

Follow LXRX, the company behind Octreotide LAR Depot

See LXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LXRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z